ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.
Recent Posts
- Henrietta Lacks’ Family Gets Undisclosed Settlement In “Immortal Cells” Case
- Stem cells provide a potent treatment for frailty
- Cracking a ‘holy grail’ challenge in cancer cell therapy
- New Bio-Implant for Spinal Cord Repair
- Seattle jury awards $24M in lawsuit against stem cell center
- Phase I/II study finds intravitreal CD34+ stem cells safe and feasible in CRVO
